Anti-HER2 Therapy Beyond Second-Line for HER2-Positive Metastatic Breast Cancer: A Short Review and Recommendations for Several Clinical Scenarios from a Spanish Expert Panel

作者：Martinez Janez Noelia^*; Chacon Ignacio; de Juan Ana; Cruz Merino Luis; del Barco Sonia; Fernandez Isaura; Garcia Teijido Paula; Gomez Bernal Amalia; Plazaola Arrate; Ponce Jose; Servitja Sonia; Zamora Pilar

来源：Breast Care, 2016, 11(2): 133-138.

DOI：10.1159/000443601

• Anti-HER2
• Metastatic breast cancer
• Clinical practice

Background: The aim of this project was to provide an expert opinion regarding anti-human epidermal growth factor receptor 2 (HER2) therapy beyond second-line treatment of metastatic breast cancer (mBC). Methods: A group of experts discussed specific issues concerning anti-HER2 therapy in late-line settings in mBC. Results: Trastuzumab emtansine (T-DM1) or dual HER2 blockade appeared to be good options for HER2-positive mBC after >= 2 HER2-targeted therapies. Once an objective response has been achieved with anti-HER2-containing therapy, the anti-HER2 agent can be continued until progression of the disease, unacceptable toxicity or patient decision. mBC treated with >= 3 consecutive lines of anti-HER therapy, >= 1 being a dual HER2 blockade and with early progression of disease during a fourth or later-line treatment, are clinically resistant to anti-HER therapy. For progression of metastasis in the brain after anti-HER2 therapy, lapatinib and chemotherapy appear to be a good alternative after best local treatment. Conclusions: Further clinical trials are needed to provide valuable knowledge about the best treatment options in the later settings of mBC.

• 出版日期2016